Lumenis Introduces Stellar M22™

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Lumenis, the inventor of IPL, is proud to introduce the next generation in Multi-Application platforms, The Stellar M22™. This system offers everything users need in one platform, while making both the physician and patient experience more seamless and successful than ever before. This launch continues Lumenis’ mission to improve the standard of care in the ever-growing, multi-billion-dollar energy-based skincare market.

“Lumenis is the pioneer in IPL, from the PhotoDerm to the M22, all of which were and are the gold standard,” said Dr. Mitchel Goldman from San Diego, California. “The Stellar M22’s efficiency is second-to-none with improved patient comfort, speed, versatility, reliability and results with better outcomes. At the end of the day, we offer patients treatments that work, which translates into increased patient satisfaction and increased profitability,” continued Dr. Goldman.

The Stellar M22 is built and based upon the gold standard of Lumenis’ original M22, and continues to carry out all treatment capabilities (i.e. treatment of vascular lesions, skin texture, tone, and hair removal) but with upgrades that make for a further amplified experience.

“The new Stellar M22™ IPL allows for easy and quick treatment with the great output and efficacy we already know from Lumenis,” said Dr. Tretti Clementoni, from Milan, Italy. He continued, “It is a huge time saver and the results are stellar!”

The latest leaps of the sixth generation IPL, Stellar M22™ include a dramatically improved user interface with a larger screen that enables a faster treatment time and more comfortable viewing from a distance. In addition, the Stellar M22™ provides a new ergonomic IPL hand piece design and longer SapphireCool™ Lightguides for better visibility of the treatment area.

“Lumenis is thrilled to introduce the new Stellar M22™, our next-generation in multi-application devices, enabling treatment of over 30 skin conditions and hair removal across skin type, gender and age,” said Tzipi Ozer-Armon, CEO of Lumenis. “Like the M22 before it, Stellar redefines the benchmark in the category and demonstrates our continued commitment to innovation and better technology for better patient care.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.